Wednesday, July 8, 2026

Drug profile · INN

tioconazole

tioconazole (VAGISTAT-1) is a cytochrome p450 51 inhibitor. Route of administration: topical. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — tioconazole
US status
approved
Class
Route
TOPICAL
Patents
0
Programs
2
Data quality
0.84

Quick answer

tioconazole (VAGISTAT-1) is a cytochrome p450 51 inhibitor. Route of administration: topical. Current US regulatory status: approved.

Key facts

INN tioconazole
Brand VAGISTAT-1
Mechanism Cytochrome P450 51 inhibitor
Target Lanosterol 14-alpha demethylase
Route TOPICAL
Formulation OINTMENT

Mechanism of action

Cytochrome P450 51 inhibitor

Primary target: Lanosterol 14-alpha demethylase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. avapritinib Phase 3 · Blueprint Medicines · GIST
  2. Ponatinib Phase 2 · Takeda · GIST

Related & competitor drugs

  1. clotrimazole Cytochrome P450 51 inhibitor
  2. efinaconazole Lanosterol 14-alpha demethylase inhibitor
  3. fluconazole Cytochrome P450 51 inhibitor
  4. itraconazole Cytochrome P450 51 inhibitor
  5. ketoconazole Antiinfectives for systemic use (J02)
  6. miconazole nitrate Cytochrome P450 51 inhibitor

Frequently asked questions

What is tioconazole?

tioconazole (VAGISTAT-1) is a cytochrome p450 51 inhibitor. Route of administration: topical. Current US regulatory status: approved.

What is the brand name for tioconazole?

VAGISTAT-1 is a marketed brand name for tioconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of tioconazole?

tioconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.